February Global Macro Monthly & Investment Strategy - Vaccine and stimulus: too much of a good thing?
- 24 February 2021 (5 min read)
Key points
- The virus is fading from a year-end resurgence in most areas of the globe. Vaccine rollout is also underway. Economies will ease COVID-related restrictions at different paces depending on circumstances. This will govern the speed of economic rebound.
- Additionally, the US appears set to unleash a powerful fiscal stimulus. This will boost economic activity this year and next, we forecast to 6.2% and 4.5%. It also looks set to close the US output gap by the end of this year, bringing closer a sustainable rise in inflation.
- Financial markets are reacting to this shifting outlook: government bond yields are rising in the US, but also elsewhere. This is leading to a pause in risk markets, although we remain positive in outlook at this stage.
- Unchecked, the rise in yields may be a problem in areas where growth is not recovering as quickly. Notably the Euro area, but also in some emerging markets.
Disclaimer
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date.
All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document.
Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.